SureTrader Nadex Advertisement
Home > Boards > US OTC > Medical - Healthcare >

Quture International, Inc. (QUTR)

Add QUTR Price Alert      Hide Sticky   Hide Intro
Moderator: inforthemoney2
Search This Board: 
Last Post: 2/27/2017 4:13:44 PM - Followers: 80 - Board type: Free - Posts Today: 6


  Home | Contact Us | Login | Register

Share This...Share on FacebookTweet about this on TwitterShare on Google+Share on LinkedIn
QualOptima is the
Q’s strategic technology platform empowers compliance with the new Joint Commission accreditation standards for FPPE-OPPE as well as regulatory requirements for many of the HITECH meaningful use measures and for prevention of readmissions and limitations for hospital acquired conditions (HAC’s); but QualOptima offers the extraordinary opportunities to exceed compliance while gaining new benefits for optimal clinical, financial and operational outcomes . . .
Clinical Intelligence System to
QualOptima is the
Q’s technology with embedded clinical content, metrics and analytics strategically empowers providers and payers to thrive in the evolving healthcare environment . . .
Performance Measurement
Clinical Intelligence System to
QualOptima is the
Q’s innovative and first to market QualOptima technology strategically analyzes outcomes from Q’s constellation of evidence-based metrics. . .
Optimal Outcomes Analytics
Clinical Intelligence System to
QualOptima is the
Q’s innovative and first-to-market QualOptima technology bundled with Q’s QualVal consulting services provides our clients with exponentially value expert resources to achieve optimal clinical, financial and operational outcomes through actionable clinical wisdom . . .
Expert Resources
Clinical Intelligence System to
QualOptima is the
Q’s technology is the first-to-market solution to meet the strategic imperative for healthcare providers to transform from fee-for-service and optimized billing strategies and software to a value-driven revenue model empowered by QualOptima . . .
Value-Driven Revenue
Clinical Intelligence System to

Quture International, Inc

Contact Info


View larger map

Share Structure
OS: 2.5B Shares.
FLOAT: 375M Shares
(2.5B x .85 = 2.125B, 2.5M - 2.125B = 375M)



The securities described in Item 1.01 above were offered and sold in reliance upon exemptions from registration pursuant to Section 4(2) under the Securities Act.  At the time of their issuance, the securities will be deemed to be restricted securities for purposes of the Securities Act, and the certificates representing the securities shall bear legends to that effect.  The securities may not be resold or offered in the United States without registration or an exemption from registration.

INSIDERS OWN 85% (AUG 9, 2011)
As a result of the Exchange, Quture became a wholly-owned subsidiary of the Registrant. Following the consummation of the Exchange, the shareholders of Quture will beneficially own approximately eighty-five percent (85%) of the issued and outstanding Common Stock of the Registrant.

So On TOP of the Restriction these shares can only be sold per insider trading rules which is something along the lines of 1% of the volume of the previous 10 trading days, etc)


Quture is an emerging healthcare knowledge solution company positioned to transform health and healthcare by developing the standard in measuring clinical performance. The Company's products and services will become the essential technology and tool to improve care and health, while reducing costs. The demand to measure performance is coming from all stakeholders in healthcare involved in both payment and delivery. Measuring performance is now mandatory and is the new foundation of how providers are reimbursed, granted privileges to practice in hospitals, and, in the near future, selected by patients for their care.

Quture is not a software company. Quture is the company that makes the best software in the world better. We know what to find, where to find it, and what to do with it once you find that data in disparate electronic data sources in healthcare organizations. The Company licenses the application of performance measures delivered in a software platform creating the most powerful clinical knowledge database in the world. Quture knows what payers want to pay for, and what they do not want to pay for, and the clinical knowledge to support payment systems while improving care.

Quture's mission statement is to become the Gold Standard in Healthcare Performance Measurement. Quture provides healthcare organizations, insurers, government payers, and other stakeholders in the healthcare community with performance measurement tools and data sets. Industry experts agree that these performance measures are the "transformative tool" that reduce medical cost and improve quality of care. Q'uture's management team has 35 years of experience and a long history of working with many of the nation's leading healthcare institutions as a leader and innovator in measuring clinical performance. Quture plans include developing a revolutionary solution to effectively and efficiently measure clinical performance from multiple vendor databases

G. Landon Feazell, Chairman & CEO

Landon Feazell is Chairman and Chief Executive Officer of Quture, Inc., positioned to become a major force in the transformation of health care and personal health. The company leverages over 35 years of measuring performance & outcomes and improving clinical quality and patient safety to anticipate the needs of providers to chart the future of quality in health care. The core capabilities of Quture are embedded in software and technology to convert data to clinical knowledge to achieve evidence-based, predictive clinical care. Mr. Feazell is nationally recognized for his leadership, innovation, and expertise in measuring clinical performance, pioneering proactive clinical risk management and patient safety and physician peer review processes. His companies have developed and implemented systems and processes in hundreds of hospitals, hospital corporations and trusts, university health systems, health maintenance organizations, large and small physician practices, federal and state governmental agencies, and health and liability insurance companies throughout the United States.

Mr. Feazell received a Bachelor of Science degree in zoology from Duke University (1965). His extensive graduate studies are in medical sciences at the West Virginia University Medical Center (1965-1967), where he was a teaching fellow, conducting research in mycology and its relationship to leukemia and preventive medicine under the direction of Ernest W. Chick, M.D., Ph.D. His graduate studies further included law at the University of Denver, College of Law (1967-1970), where he was student assistant to the deans. He served as Chairman of the National Conference of Law Reviews (1968-69) and after graduation has served as Chairman of the Board Council of Community Mental Health Centers and chaired board training grants for these centers for a federal region. His community service includes chairing many public education initiatives for Jefferson County Board of Education and successful political campaign cabinets for Governor and United States Senator in Colorado. He is widely published in professional articles, and he lectures, teaches, and participates on national expert panels at universities, professional organizations, private corporations, and forums and seminars and has taught at the undergraduate and graduate level at several universities.


Janice J. Ophoven, MD, Associate Medical Director (QualOptima)

Dr. Janice Ophoven is a pediatric forensic pathologist with over thirty years of clinical, administrative and quality improvement experience. She is board certified in Pathology, Forensic Pathology, Quality Assurance and Utilization Review. Dr. Ophoven has focused her clinical practice on understanding child abuse and injury to children.

Dr. Ophoven is an internationally recognized and a court-certified medical expert in pediatric forensic pathology. She has consulted and/or testified in civil and criminal cases in the US and abroad for both defense and prosecution when injury or death to a child has occurred. For these cases and as a consultant to Medical Examiners/coroners, physicians, law enforcement, and legal professionals she has been asked to determine the cause and manner of a child's injury or death.

She is also a consultant and nationally recognized speaker and educator on Forensic Pathology as well as on quality improvement of health care systems. She has worked with physicians, clinicians and hospital systems at organizations such as, Children's Hospital-St. Paul, MN; and Allina Health System, MN: Montefiore Hospital (Albert Einstein University), NY to improve quality system-wide.

Through her years of experience, Dr. Ophoven has pioneered an innovative and successful evidence-based model that draws on medical science and practicing clinicians to identify risk and challenge barriers to successful medical care.

In 1981, Dr. Ophoven founded her firm specializing in pediatric forensic pathology services. Her work has included cases of Munchausen's Syndrome By Proxy (MSBP), infanticide, sexual misuse, infant apnea/SIDS, suffocation, and accidental and inflicted head trauma. Her work requires both in-depth knowledge of medical sciences and forensics including: General Pediatric Pathology and Laboratory Medicine, Developmental and Gestational Pathology, as well as Pediatric Autopsy and Injury Analysis, Pediatric Laboratory Medicine, Pediatric Hematopathology, and Pediatric Pulmonary Disease.


Keith Candiotti, MD, Associate Medical Director (QSurg)

  • Chief of the Division of Perioperative Medicine, Department of Anesthesiology, University of Miami Miller School of Medicine
    Vice Chairman of Clinical Research, Department of Anesthesiology, University of Miami School of Medicine
    Associate professor of anesthesiology
    Miami, Florida

Dr. Keith Candiotti is a graduate of the University of Miami Miller School of Medicine, where he completed a residency in internal medicine in 1992 and a residency in anesthesiology in 1994 and went on to join the Department of Anesthesiology. He currently serves as Chief of the Division of Perioperative Medicine and Vice Chairman of Clinical Research within the department. Additionally, he has coappointments in the departments of Internal Medicine, Urology, and Obstetrics and Gynecology.

Dr. Candiotti has conducted numerous clinical trials, including US Food and Drug Administation studies in the areas of postoperative nausea and vomiting (PONV), pain, consciousness monitoring, and other various clinical areas. His personal research interests are in the areas of perioperative inflammatory responses; pharmacogenomics and how it relates to pain and perioperative outcomes, PONV, and preoperative evaluation; and the management of patients exposed to weapons of mass destruction. He is a member of the American Society of Anesthesiologists Committee on Research and was recently appointed as Chairman of the Society of Ambulatory Anesthesia Research Committee.

Dr. Candiotti has published numerous articles and abstracts at various medical meetings. He currently lectures both in the United States and around the world on topics related to his areas of interest.


Judith K. Daugherty, RN, PhD, Director, Multi-Disciplinary Clinical Content

Dr. Daugherty co-founded Excelcare, Inc., in 1984 and serves as its President/CEO. The Excelcare product is the leading nursing care plan and documentation system for nursing expected outcomes. The software introduced the innovative nursing software technology for five functions: Planning/Clinical Pathways, Documenting, Quality Management, Staffing and Costing. The Excelcare product has been successfully marketed and implemented in the USA, Australia, Asia, and Europe. Dr. Daugherty has served in a consultation role for Lockheed Martin Federal Systems Health Division, CareGroup System (Boston) and Price Waterhouse Senior Management Consultant in hospital and nursing engagements. Prior to Excelcare, she was Associate Administrator Mercy Hospital (PA). She has organized, sponsored and/or presented at domestic and international professional education seminars for all levels of healthcare professionals, as well as being Adjunct Professor (Nursing): Hunter College (NY, NY) and University of Pittsburgh (PA) and Professor (Masters Nursing Administration Program): Duquesne University (Pittsburgh, PA). Her community service includes being Past Chairman of PA Board of Directors, American Heart Association.



Tuesday, November 13, 2012

Quture Recruits Healthcare Visionary and Accomplished Expert to Strengthen Distinguished Management Team      MWUS(Tues, Nov 13)

Monday, August 27, 2012

Quture/TCLN QualOptima Product Business Case Expands Focus to Patient-Centered Personalized Medicine Marketwire(Mon, Aug 27)

Wednesday, August 8, 2012  

Quture/TCLN QualOptima Product on Target With Hospital Urgent Needs to Acquire Clinical Analytics Tools  Marketwire(Wed, Aug 8)

Monday, July 30, 2012

Quture/TCLN Announces Successful Completion Of Interdisciplinary Product At Niagra Falls Memorial Hospital Preparing For Comm..  PRNUS(Mon, Jul 30)

Wednesday, July 11, 2012

Quture/TCLN & Springhill Medical Center Jointly Announce Sale of Software License to Qualoptima  Marketwire(Wed, Jul 11)

Thursday, June 21, 2012

Quture/TCLN Issues Shareholder Letter and Update Marketwire(Thur,  Jun 21)

Tuesday, June 12, 2012

      . Quture International, Inc. / TCLN Announces Pre-Launch Completion of QualOptima Commercial Product Marketwire(Tues, Jun 12)

Monday, May 14, 2012

     .  Quture/TCLN Announces Formation of Subsidiary for European Operations Marketwire(Mon, May 14)

Tuesday, March 27, 2012

     .  Quture International, Inc. / TCLN Announces Successful Completion to QualOptima Product Demonstration. Marketwire(Tues, Mar 27)
Thursday, March 15, 2012

        .Techs Loanstar, Inc. Announces Corporate Name Change to Quture International, Inc.Marketwire(Thurs, Mar 15)

Tuesday, December 20, 2011

      .  Quture/TCLN Annousnces First Commercial  Application on Intersystems Platform  Marketwire(Tues, Dec 20)

Thursday, November 10, 2011

Monday, September 26, 2011

Tuesday, September 6, 2011

Tuesday, August 23, 2011

Monday, July 25, 2011

Tuesday, June 28, 2011

Monday, June 27, 2011




  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
#6045  Sticky Note QUTR investors have asked about Quture's participation in Tobinn 02/27/17 02:02:06 PM
#6050   Yes we are very very close!! BIGDADMAC 02/27/17 04:13:44 PM
#6049   I believe that the HFACS Software is just inforthemoney2 02/27/17 02:51:44 PM
#6048   Landon's latest tweet: We had a big week BIGDADMAC 02/27/17 02:16:03 PM
#6047   All about branding and getting your name in inforthemoney2 02/27/17 02:14:04 PM
#6046   Thanks for posting Tobinn.. Qutr inforthemoney2 02/27/17 02:07:31 PM
#6045   QUTR investors have asked about Quture's participation in Tobinn 02/27/17 02:02:06 PM
#6044   Saw some interesting Facebook activity on quture. If Tobinn 02/26/17 07:20:49 PM
#6043   Medicomp debuts latest point-of-care decision support tool at BIGDADMAC 02/25/17 07:46:09 PM
#6042   Couple of nice slaps on 8s..Not many left now..QUTR inforthemoney2 02/23/17 10:47:32 AM
#6041   LF with Intersystems at HIMSS 17 inforthemoney2 02/23/17 10:01:50 AM
#6040   I agree completely. Epic would be the most BIGDADMAC 02/22/17 09:26:23 PM
#6039   Intersystems is the backbone of the programming used Tobinn 02/22/17 09:11:04 PM
#6038   In my opinion, and it is purely only gauvdog 02/22/17 05:51:18 PM
#6037   Good questions, Fido! gauvdog 02/22/17 05:45:52 PM
#6036   I just sent a email to HFACS Healthcare inforthemoney2 02/22/17 11:49:15 AM
#6035   I hear you Tobinn. I think I know BIGDADMAC 02/22/17 11:38:37 AM
#6034   Good luck with that, apparently he's too busy tweeting. Fido 02/22/17 06:41:43 AM
#6033   I'll agree that LF should be thinking nothing Fido 02/22/17 06:40:36 AM
#6032   Seems like quture is looking for a buyout Tobinn 02/21/17 11:54:53 PM
#6031   Enough already with tweeting. Has it raised Fido 02/21/17 07:49:32 PM
#6030   Landon seems to really be busy and the BIGDADMAC 02/21/17 03:21:54 PM
#6029   If Landon does not answer my multiple Emails Omu 02/21/17 01:12:19 PM
#6028   Omu 02/21/17 12:46:27 PM
#6027   I agree. LF's latest tweets shows pics from inforthemoney2 02/21/17 10:04:21 AM
#6026   You need to go to himss17 website and maggco 02/21/17 09:53:43 AM
#6025   That is correct and well said! chance4 02/21/17 09:50:37 AM
#6024   I know he is there for a fact BIGDADMAC 02/21/17 09:17:49 AM
#6023   Vendors List for HIMSS 17 inforthemoney2 02/21/17 08:58:49 AM
#6022   I thought quture was being represented by intersystems( PT128 02/21/17 06:55:35 AM
#6021   Good DD! Will you please post the gauvdog 02/21/17 05:57:32 AM
#6020   Just check HISS17 exhibitors list and Quture is maggco 02/20/17 09:53:08 PM
#6019   He can tweet all he wants, after all Fido 02/20/17 08:09:20 PM
#6018   LF tweet. inforthemoney2 02/20/17 11:09:21 AM
#6017   "leading high tech healthcare analytics and software company". gauvdog 02/18/17 07:22:10 PM
#6016   Hmmm, that breadcrumb smacks of a program stoxx00 02/18/17 10:40:08 AM
#6015   HFACS healthcare web site does mention a partnership inforthemoney2 02/17/17 10:50:32 AM
#6014   It'd be nice if the HFAC website would gauvdog 02/17/17 08:44:30 AM
#6013   Upcoming April 17 work shop for HFACS Healthcare inforthemoney2 02/17/17 08:22:39 AM
#6012   Landon's latest tweet; Will Obamacare Really Go Under BIGDADMAC 02/16/17 11:17:11 PM
#6011   Less than a week away Himss 17 could inforthemoney2 02/16/17 04:31:08 PM
#6010   I added today. Anyone else?? PT128 02/14/17 02:38:37 PM
#6009   #HMISS17 Perspective: Connected Healthbots Will Wake up Clinical BIGDADMAC 02/13/17 04:47:37 PM
#6008   Yep, not looking overly rosy at the moment. Fido 02/13/17 03:48:58 PM
#6007   that was fun while it lasted..... Pip611 02/13/17 03:48:14 PM
#6006   I have no doubt he will be there, BIGDADMAC 02/13/17 02:43:03 PM
#6005   LF has been referencing HIMSS 17 in inforthemoney2 02/12/17 11:24:30 AM
#6004   That's what we want to hear... useful link stoxx00 02/11/17 12:18:41 PM
#6003   HIMSS17 must attends: MACRA, Trump Healthcare Changes Deliberated BIGDADMAC 02/10/17 03:31:21 PM
#6002   This could be the start of something HUGH!! BIGDADMAC 02/08/17 02:40:10 PM
#6001   Interesting up 45% on low volume..Looks like a inforthemoney2 02/08/17 12:50:29 PM